DCAT’s 2008 “PharmaChem Outlook” presented by Thomson Wednesday, March 12, 2008 Waldorf-Astoria Hotel, New York 8:00 am to 11:45 am, Empire Room
Registration for this program is now closed.  Walk-in attendees are welcome the day of the program. Only credit card payments will be accepted on site.
The cancelation deadline for this program was Monday, March 3rd at 12:00pm EST.  In order to receive a full refund, you must have submitted your cancellation request prior to that date.

DCAT is pleased to present this annual program that provides industry representatives with an overview of current issues and trends that affect their business.  This year, DCAT has invited Thomson Scientific, a worldwide information solutions company assisting the PharmaChem industry in a variety of areas, as the lead presenter.  The program will include an audience interactive session and will cover topics that will be invaluable to program participants. 

Program Topics to Include:

Industry Trends: Perception vs. Reality - What is really going on in the pharmaceutical industry? Thomson will share with you insights on the state of the industry. In this lively session you’ll be a part of the action, thanks to interactive voting technology. You’ll have your own remote voting handset to anonymously submit your opinion as live results reveal perceptions.  Walk away with lots of valuable information to better manage the risks and exploit the opportunities as the reality is unmasked. Key trends to be covered: Utilization, R&D, Generics and API, Regulatory and Financial Implications.

Innovators and Generics: Are the Lines Blurring? - As the climate’s turn against the old blockbuster model we see innovators head into the generic market. But why are generics companies crossing over into innovation too? In this fascinating session, Thomson Scientific will outline the critical success factors causing companies on both sides of the debate to rethink their strategies. Key topics to include:

• What is driving generics toward innovation and innovators toward generics?
• What are the critical success factors?
• Is this the right strategy for everyone?
• What will the future bring?

Emerging Markets (Europe, Russia, India, China): Opportunities, Rather Than Threats - Gain valuable insight as Thomson Scientific, API Intelligence (formerly known as Newport Strategies), and industry leaders in generic and API intelligence, validate and analyze which emerging economies have a bright future in pharmaceuticals and what the intelligence is telling us. Key topics to include: markets for APIs, markets for dose, R&D and manufacturing base.

Program Fees: Member Company - $99.00, Non-Member Company - $299.00.

About the Speakers:

Speakers will include Thomson personnel from several key sectors including contributions from Thomson Scientific, Thomson Healthcare, Thomson Financial, Prous Science, IDRAC, The Centre for Medicines Research International Ltd (CMR), and Newport Strategies.

This program was developed by the DCAT Outlook Task Force and Thomson Scientific.